Furthermore, specific APP processing, as observed in aOPCs cultured at 0 or 1 ng/ml FGF2 (Fig. 3d and Supplementary Fig. 6F), may be a promising therapeutic target for sporadic AD, although future studies are warranted for validation. This evidence concerns the gene FGF2 and Alzheimer disease.